These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 30124150)

  • 1. Potential Enzymatic Targets in Alzheimer's: A Comprehensive Review.
    Alam J; Sharma L
    Curr Drug Targets; 2019; 20(3):316-339. PubMed ID: 30124150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. γ-Secretase as a target for Alzheimer's disease.
    Wolfe MS
    Adv Pharmacol; 2012; 64():127-53. PubMed ID: 22840746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in the identification of γ-secretase inhibitors for the treatment of Alzheimer's disease.
    D'Onofrio G; Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Paroni G; Cascavilla L; Seripa D; Pilotto A
    Expert Opin Drug Discov; 2012 Jan; 7(1):19-37. PubMed ID: 22468891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of glycogen synthase kinase-3 in Alzheimer's disease pathogenesis and glycogen synthase kinase-3 inhibitors.
    Avila J; Wandosell F; Hernández F
    Expert Rev Neurother; 2010 May; 10(5):703-10. PubMed ID: 20420491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tau therapeutic strategies for the treatment of Alzheimer's disease.
    Churcher I
    Curr Top Med Chem; 2006; 6(6):579-95. PubMed ID: 16712493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Therapy of Alzheimer disease].
    Kovács T
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alzheimer's disease drug development based on Computer-Aided Drug Design.
    Zeng H; Wu X
    Eur J Med Chem; 2016 Oct; 121():851-863. PubMed ID: 26415837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secretase inhibitors and modulators for Alzheimer's disease treatment.
    Tomita T
    Expert Rev Neurother; 2009 May; 9(5):661-79. PubMed ID: 19402777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel glycogen synthase kinase-3 inhibitor 2-methyl-5-(3-{4-[(S )-methylsulfinyl]phenyl}-1-benzofuran-5-yl)-1,3,4-oxadiazole decreases tau phosphorylation and ameliorates cognitive deficits in a transgenic model of Alzheimer's disease.
    Onishi T; Iwashita H; Uno Y; Kunitomo J; Saitoh M; Kimura E; Fujita H; Uchiyama N; Kori M; Takizawa M
    J Neurochem; 2011 Dec; 119(6):1330-40. PubMed ID: 21992552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interacting with γ-secretase for treating Alzheimer's disease: from inhibition to modulation.
    Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
    Curr Med Chem; 2011; 18(35):5430-47. PubMed ID: 22087836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. γ-secretase inhibitors and modulators for the treatment of Alzheimer's disease: disappointments and hopes.
    Imbimbo BP; Giardina GA
    Curr Top Med Chem; 2011; 11(12):1555-70. PubMed ID: 21510832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Valproic Acid Modifies Synaptic Structure and Accelerates Neurite Outgrowth Via the Glycogen Synthase Kinase-3β Signaling Pathway in an Alzheimer's Disease Model.
    Long ZM; Zhao L; Jiang R; Wang KJ; Luo SF; Zheng M; Li XF; He GQ
    CNS Neurosci Ther; 2015 Nov; 21(11):887-97. PubMed ID: 26385876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic intervention for Alzheimer's disease with γ-secretase inhibitors: still a viable option?
    Imbimbo BP; Panza F; Frisardi V; Solfrizzi V; D'Onofrio G; Logroscino G; Seripa D; Pilotto A
    Expert Opin Investig Drugs; 2011 Mar; 20(3):325-41. PubMed ID: 21222550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beyond the neurotransmitter-focused approach in treating Alzheimer's disease: drugs targeting beta-amyloid and tau protein.
    Panza F; Solfrizzi V; Frisardi V; Imbimbo BP; Capurso C; D'Introno A; Colacicco AM; Seripa D; Vendemiale G; Capurso A; Pilotto A
    Aging Clin Exp Res; 2009 Dec; 21(6):386-406. PubMed ID: 20154508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of Alzheimer's disease-An insight of the enzymatic and other novel potential targets.
    Islam BU; Tabrez S
    Int J Biol Macromol; 2017 Apr; 97():700-709. PubMed ID: 28111296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Secretases as therapeutic targets for the treatment of Alzheimer's disease.
    Dominguez DI; De Strooper B; Annaert W
    Amyloid; 2001 Jun; 8(2):124-42. PubMed ID: 11409035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroprotective effects of bergenin in Alzheimer's disease: Investigation through molecular docking, in vitro and in vivo studies.
    Barai P; Raval N; Acharya S; Borisa A; Bhatt H; Acharya N
    Behav Brain Res; 2019 Jan; 356():18-40. PubMed ID: 30118774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GSK-3 inhibitors for Alzheimer's disease.
    Avila J; Hernández F
    Expert Rev Neurother; 2007 Nov; 7(11):1527-33. PubMed ID: 17997701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural Compounds with Anti-BACE1 Activity as Promising Therapeutic Drugs for Treating Alzheimer's Disease.
    Naushad M; Durairajan SSK; Bera AK; Senapati S; Li M
    Planta Med; 2019 Nov; 85(17):1316-1325. PubMed ID: 31618777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic potentials of plant iridoids in Alzheimer's and Parkinson's diseases: A review.
    Dinda B; Dinda M; Kulsi G; Chakraborty A; Dinda S
    Eur J Med Chem; 2019 May; 169():185-199. PubMed ID: 30877973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.